Compare LEN & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEN | GEHC |
|---|---|---|
| Founded | 1954 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Computer Software: Prepackaged Software |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0B | 35.8B |
| IPO Year | N/A | 2022 |
| Metric | LEN | GEHC |
|---|---|---|
| Price | $94.67 | $70.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $104.23 | $90.83 |
| AVG Volume (30 Days) | 2.4M | ★ 2.7M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 2.06% | 0.19% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | N/A | ★ 4.55 |
| Revenue | N/A | ★ $20,625,000,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | $4.82 | $4.50 |
| P/E Ratio | ★ $15.20 | $15.86 |
| Revenue Growth | N/A | ★ 4.84 |
| 52 Week Low | $92.17 | $57.65 |
| 52 Week High | $144.24 | $89.77 |
| Indicator | LEN | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 29.68 | 30.49 |
| Support Level | N/A | $69.64 |
| Resistance Level | $118.16 | $74.29 |
| Average True Range (ATR) | 2.96 | 2.04 |
| MACD | -1.04 | -0.73 |
| Stochastic Oscillator | 10.96 | 7.69 |
Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).